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In previous immuno-epidemiological studies of the naturally acquired antibody responses to merozoite sur-
face protein-1 (MSP-1) of Plasmodium vivax, we had evidence that the responses to distinct erythrocytic stage
antigens could be differentially regulated. The present study was designed to compare the antibody response to
three asexual erythrocytic stage antigens vaccine candidates of P. vivax. Recombinant proteins representing the
19 kDa C-terminal region of MSP-1(PvMSP19), apical membrane antigen n-1 ectodomain (PvAMA-1), and the
region II of duffy binding protein (PvDBP-RII) were compared in their ability to bind to IgG antibodies of serum
samples collected from 220 individuals from the state of Pará, in the North of Brazil. During patent infection
with P. vivax, the frequency of individuals with IgG antibodies to PvMSP119, PvAMA-1, and PvDBP-RII were 95,
72.7, and 44.5% respectively. Although the frequency of responders to PvDBP-RII was lower, this frequency
increased in individuals following multiple malarial infections. Individually, the specific antibody levels did
not decline significantly nine months after treatment, except to PvMSP119. Our results further confirm a com-
plex regulation of the immune response to distinct blood stage antigens. The reason for that is presently un-
known but it may contribute to the high risk of re-infection in individuals living in the endemic areas.
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Plasmodium vivax is the second most prevalent
specie that causes malaria in humans (Mendis et al.
2001). In Brazil, P. vivax was responsible by approxi-
mately 75% of 597,907 cases reported in 2005 (Se-
cretaria de Vigilância em Saúde, Ministério da Saúde).
In spite of its high prevalence in Brazil as in many other
parts of the world, the immunological mechanisms op-
erating in individuals exposed to P. vivax have been very
poorly explored.
In recent years, we have carried out several immuno-
logical studies using malaria recombinant proteins cor-
responding to the P. vivax merozoite surface protein 1
(MSP-1) and apical membrane antigen 1 (AMA-1)
(Soares et al. 1997, 1999, Rodrigues et al. 2003, 2005).
These immuno-epidemiological studies on naturally ac-
quired immunity to merozoite proteins are of particular
importance as these MSP-1 and AMA-1 are being inten-
sively studied as a candidate for development of a vac-
cine against malaria (Good 2005). So far, we found that
a high frequency of individuals from the Brazilian Ama-
zon area, where P. vivax is endemic, had IgG antibodies
to recombinant proteins based on 19 kDa C-terminal
region of MSP-1 (PvMSP119) (Soares et al. 1997, 1999,
Rodrigues et al. 2003) and the AMA-1 ectodomain
(PvAMA-1) (Rodrigues et al. 2005, Oliveira et al. 2006).
As a continuation of our immuno-epidemiological
studies in Brazil, in the present study, we compared the
IgG antibody response to recombinant proteins based on
three asexual erythrocytic stage antigens vaccine candi-
dates of P. vivax, including the region II of the duffy
binding protein (PvDBP-RII).
MATERIALS AND METHODS
Human serum samples - Serum samples were col-
lected during the period from 1995 to 1999 from 220
patients living in endemic areas for malaria in the state
of Pará, in the North of Brazil. At the time of blood col-
lection, these subjects were positive for P. vivax by con-
ventional thick blood smears microscopic examination.
Details on the study area, patient age and diagnosis have
been reported previously (Soares et al. 1997, 1999,
Rodrigues et al. 2003, 2005, Oliveira et al. 2006). Only
individuals whom precise information on the number of
P. vivax malaria episodes was available were used to es-
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tablish a correlation between the number of malarias and
the frequency of responders to recombinant proteins. A
second group of individuals (n = 33) donated blood nine
months after being treated for malaria. Those individu-
als did not report subsequent malaria infections in that
period. A third group of individuals was healthy adult
volunteers selected among blood donors from the city
of São Paulo, state of São Paulo, in the Southeastern of
Brazil (n = 26). Malaria is not present in this part of the
country and these individuals had never had malaria or trav-
eled to malaria endemic areas. The Ethics Committee of
the University of São Paulo has approved our studies.
Recombinant proteins
PvMSP119 - The recombinant protein PvMSP119 rep-
resents the 19 kDa C-terminal region of the P. vivax
MSP-1. This protein was expressed in Escherichia coli
and purified as publish elsewhere (Cunha et al. 2001).
PvAMA-1 - The recombinant representing the
PvAMA-1 ectodomain was made as already reported
(Rodrigues et al. 2005).
PvDBP-RII - The recombinant protein PvDBP-RII rep-
resents region II of P. vivax DBP. This protein was ex-
pressed in E. coli and purified as previously described
(Singh et al. 2001).
ELISA for detection of human IgG antibodies - Hu-
man IgG antibodies against PvMSP119 , PvAMA-1, and
PvDBP-RII were detected by ELISA as described
(Rodrigues et al. 2003, 2005). The results were ex-
pressed as index of reactivity (IR = OD492 values of test
sample divided by the value of the cutoff). Cutoff points
were set at three standard deviations above the mean
OD492 of sera from 26 individuals, unexposed to ma-
laria, from the city of São Paulo. Values of IR ≥ 1.0 were
considered as positive.
Statistical analysis - Differences between propor-
tions of responders were analyzed using the Chi-square
test. Comparison of antibody level (IR) of independent
samples was performed using one-way analysis of vari-
ance (ANOVA). Wilcoxon Signed Rank test was used to
compare dependent samples.
RESULTS
Comparison of IgG antibody response of individu-
als during patent P. vivax infection to recombinant
proteins representing MSP119, AMA-1, and DBP-RII
of P. vivax - Initially, we compared the IgG antibody re-
sponse of individuals during acute infection to the re-
combinant proteins representing PvMSP119, PvAMA-1,
and PvDBP-RII. The frequency of individuals with IgG
antibodies to all three proteins during patent infection
was only 37.7%. No response to any antigen was ob-
served in only 2.7% of individuals. Fig. 1 shows the fre-
quency of responders against each recombinant protein.
The results showed that the frequency of individuals that
presented IgG antibodies to recombinant proteins
PvMSP119, PvAMA-1, and PvDBP-RII were 95, 72.7,
and 44.5%, respectively. These data confirmed that all
three proteins are immunogenic during natural infec-
tions. The prevalence of antibodies against PvMSP119
was significantly higher than the prevalence against
PvAMA-1 (Chi-Square test, P < 0.0001). The prevalence
for both were higher than those observed for PvDBP-
RII (Chi-Square test, P < 0.0001).
 When we compared the IR
 
values from individual
serum samples, we observed that values obtained for
PvMSP119 were higher than all other groups (Table I).
The IR values to PvDBP-RII were lower than those ob-
served to PvAMA-1 (One Way ANOVA, P < 0.0001).
We then determined whether there was a correlation
between the frequency of IgG antibodies and episodes
of P. vivax infection. For this purpose, the sera of the
213 individuals were separated in two groups: (i) pri-
TABLE I
Magnitude of the IgG antibody response in 220 individuals with
patent Plasmodium vivax malaria
Recombinant            IgG antibody level
protein  IR 95% CI
PvMSP119 11.41  10.73 – 12.09
PvAMA-1 3.44    2.96 –  3.92
PvDBP-RII 1.46    1.23 –  1.69
The antibody level was expressed as mean of index reactivity (IR,
95% CI) that corresponds to OD492 value of test sample obtained
at 1:100 serum dilution divided by the value of the cutoff. The
cutoff value was the mean OD492 value plus three standard

















Fig. 1: antibody response to recombinant proteins corresponding to the
MSP119, AMA-1, and DBP-RII of Plasmodium vivax during patent P.
vivax infection. Serum samples were tested at 1:100 serum dilution. Per-
centage of responders was estimated from 220 individuals and corre-
sponds to  those serum samples that presented OD492 values 3 standard
deviations above the average OD492 obtained from serum samples of 26
healthy individuals never exposed to malaria. Values of IR ≥ 1.0 were
considered as positive.















PvMSP119        PvAMA-1        PvDBP-RII
Primary-infected (n = 145)
Multiple-infected (n = 68)
*
*
Fig. 2: association between the percentage of responders that rec-
ognize each recombinant protein and the number of previous ma-
laria episodes. A total of 213 individuals were grouped according to
the number of episodes of Plasmodium vivax malaria. The number
of individuals of each group was 145 and 68 from primary and mul-
tiple infected people, respectively. Percentage of responders was
estimated according to Fig. 1. Asterisks indicate frequency of re-
sponders statistically significant among individuals primary-infected
and with multiple infections.
body levels (estimated by OD492) to the different recom-
binant proteins. The proportions of individuals with an-
tibodies specific to PvAMA-1 and PvDBP-RII were not
significant during the infection or after treatment (Chi-
Square test, P < 0.05). The low frequency of responders
to PvDBP-RII can be explained by the fact that only pri-
mary infected individuals constitute this group. In con-
trast, the proportions of individuals with antibodies spe-
cific to PvMSP119 were statistically higher during in-
fection than nine months after treatment (Chi-Square
test, P < 0.0001).
When the antibody levels of individuals who recog-
nized each recombinant protein were estimated (Table
II), we found that these levels were not significant dur-
ing the infection and after treatment, except to PvMSP119(Wilcoxon Signed Ranks test, P < 0.0001).
mary-infected, individuals with no previous malaria epi-
sodes (n = 145) and (ii) individuals with one or more
previous malaria episodes (n = 68). We found that the
frequency of responders to PvMSP119 did not change
significantly when we divided them in primary and mul-
tiple-infected (Chi-Square test, P > 0.05) confirming
data previously obtained by our group that showed that
antibody response against PvMSP119 was established
after a single exposure to malaria (Rodrigues et al. 2003,
2005). In contrast, the frequency of serum samples con-
taining IgG against PvAMA-1 and PvDBP-RII was sig-
nificantly lower in group primary-infected when com-
pared with the group multi-infected individuals (Chi-
Square test, P < 0.0001), suggesting that the serocon-
version to these proteins occurs after multiple exposures
to malaria infection (Fig. 2). However, no difference was
observed between the frequency of positive sera during
the second/third or more malaria episodes, showing that
specific IgG responses to both antigens developed after
few malaria episodes (data not shown).
Longevity of the IgG antibody response to recom-
binant proteins representing MSP119, AMA-1 and DBP-
RII of P. vivax - In earlier studies, we observed that the
IgG antibody titers to recombinant proteins represent-
ing the N- and C-terminal regions of P. vivax MSP-1
declined significantly after treatment (Soares et al. 1999).
Using serum samples collected during patent infection
and nine months after treatment (paired groups, n = 33),
we compared the frequency of responders and the anti-
DISCUSSION
In the present study we compared the recognition by
human IgG antibodies of recombinant proteins represent-
ing three asexual erythrocytic stage vaccine candidates
of P. vivax (MSP119, AMA-1, and DBP-RII). Initially,
we confirmed that the frequency of individuals who pre-
sented IgG antibodies to PvMSP119 and PvAMA-1 dur-
ing patent infection was high and comparable to the fre-
quency observed in our recent studies (Rodrigues et al.
2003, 2005). On the other hand, the frequency of re-
sponders to DBP-RII was significantly lower. One pos-
sible explanation for this fact could be the requirement
of repeated exposures to parasite antigens in order to
promote seroconvertion. Eventually, repeated P. vivax
infections could significantly increase the frequency of
responders, indicating that most individuals may become
responders depending on the degree of exposure. To an-
swer that question, we divided the individuals that in-
formed the number of previous malaria episodes in two
groups: primary-infected and individuals with one or
TABLE II
Comparison of frequency and antibody serum sample levels of
each recombinant protein among individuals with acute
Plasmodium vivax infection and after treatment
                       Paired group (n = 33)
Recombinant Patent infection After treatment
protein % IR % IR
PvMSP119 100.0      7.81 57.6 * 1.43 *
PvAMA-1   81.8      2.04 87.9 1.73
PvDBP-RII   15.1      0.34   6.1 0.25
Percentage of responders was estimated according to Fig. 1. The
antibody level to each recombinant protein is expressed as the
median of index reactivity (IR). Asterisks indicate frequency of
responders or antibody levels statistically significant among
individuals with acute infection and after treatment.
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more previous malaria episodes. Our analysis showed
that the frequency of responders to PvAMA-1 and
PvDBP-RII was higher in the multiple-infected. This data
suggests that multiple infections provide a boost to the
production of specific antibodies confirming recent
observations obtained in other studies in distinct endemic
areas of Brazilian Amazon (Ceravolo et al. 2005, Tran et
al. 2005). In the case of PvMSP119, specific IgG re-
sponses developed faster after a single exposition to
malaria infection, also confirming previous observations
of distinct groups that PvMSP119 is highly immunogenic
during natural human infections (Park et al. 2001, Lim
et al. 2002, Rodrigues et al. 2003, Morais et al. 2005,
Wickramarachchi et al. 2007).
We also evaluated the persistence of antibody re-
sponse to the different recombinant proteins in individu-
als exposed to P. vivax. We compared the presence of
specific antibodies and their levels in a period of nine
months following P. vivax infection in the absence of
reinfection. During acute infection, eleven individuals
(33.3%) displayed antibodies to all three proteins. After
treatment, all those individuals persisted serologically
positive to at least one antigen. When evaluated each in-
dividual recombinant protein, in the majority of individu-
als, specific IgG antibodies did not diminish significantly
in that period, except to PvMSP119. This observation
confirms our earlier description that during acute infec-
tion, there was a significant higher frequency of respond-
ers who had higher IgG antibody titers to PvMSP119 when
compared to individuals few months after treatment for
malaria (Soares et al. 1997, 1999). The significant de-
cay of the number of positive sera and antibody levels to
PvMSP119 contrasted with the fact that the frequency of
responders to PvAMA-1, increased slightly after treat-
ment. The vast majority of the individuals (85.7%) that
became serologically negative to PvMSP119 maintained
detectable antibodies to PvAMA-1. Similar results were
recently obtained in a distinct endemic area of Brazilian
Amazon which showed that anti-PvAMA-1 antibodies
persisted in > 40% of those subjects exposed to focal
malaria eight months before (Morais et al. 2006).
The reason why the antibody production is differ-
entially sustained to each recombinant antigen after
treatment is currently unknown and deserves to be in-
vestigated further in the future. Effective treatment
of malaria infections has been shown to lead to rapid
decline in antibody concentrations. In spite of that,
memory B cells can persist in the absence of antigen
and can be rapidly reactivated on reinfection (reviewed
by Struik & Riley, 2004).
In summary, our results show that all three vaccine
candidates are immunogenic molecules during natural
malaria infections and these recombinant proteins may
be useful tools to perform immuno-epidemiological
studies in malaria endemic areas and to further studies
towards the vaccine potential of these proteins.
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